Amarin completes patient enrollment in Huntington's disease trial

By Elaine Rigoli

Tampa, Fla., July 27 - Amarin Corp. plc said it completed enrollment of the 240 patients targeted for its European phase 3 clinical trial of Miraxion to treat Huntington's disease (HD) ahead of schedule.

The study is being conducted in collaboration with Euro-HD at 27 neurology centers in Austria, Germany, Italy, Portugal, Spain and the United Kingdom.

The company said the trial is evaluating the effects of Miraxion compared with a placebo using the Total Motor Score-4 subscale of the Unified Huntington's Disease rating scale.

The company said the goal is for patients treated with Miraxion at a dose of two grams per day (one gram twice daily) for six months to demonstrate significant improvements in their motor functioning.

Amarin is a neuroscience company located in London.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.